This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Garber, K. RIKEN suspends first clinical trial involving induced pluripotent stem cells. Nat Biotechnol 33, 890–891 (2015). https://doi.org/10.1038/nbt0915-890
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt0915-890
This article is cited by
-
Challenges in the clinical advancement of cell therapies for Parkinson’s disease
Nature Biomedical Engineering (2023)
-
TPX2 Amplification-Driven Aberrant Mitosis in Culture Adapted Human Embryonic Stem Cells with gain of 20q11.21
Stem Cell Reviews and Reports (2023)
-
Bioengineering strategies for restoring vision
Nature Biomedical Engineering (2022)
-
Clinical Considerations for RPE Cell Transplantation
Current Ophthalmology Reports (2022)